BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23642948)

  • 1. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy.
    Coulson S; Rao A; Beck SL; Steels E; Gramotnev H; Vitetta L
    Complement Ther Med; 2013 Jun; 21(3):172-9. PubMed ID: 23642948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytotherapy for benign prostatic hyperplasia.
    Wilt TJ; Ishani A; Rutks I; MacDonald R
    Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy.
    Kaplan SA
    J Urol; 2014 Jul; 192(1):164. PubMed ID: 25629105
    [No Abstract]   [Full Text] [Related]  

  • 5. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
    Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Ye Z; Huang J; Zhou L; Chen S; Wang Z; Ma L; Wang D; Wang G; Wang S; Liang C; Qiu S; Gu X; Liu J; Weng Z; Wu C; Wei Q; Xie L; Wu W; Cheng Y; Hu J; Wang Z; Zeng X
    Urology; 2019 Jul; 129():172-179. PubMed ID: 30880074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pygeum africanum for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R; Rutks I; Stark G
    Cochrane Database Syst Rev; 2002; 1998(1):CD001044. PubMed ID: 11869585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies.
    Mantovani F
    Minerva Urol Nefrol; 2010 Dec; 62(4):335-40. PubMed ID: 20944533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; MacDonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
    Morgia G; Russo GI; Voce S; Palmieri F; Gentile M; Giannantoni A; Blefari F; Carini M; Minervini A; Ginepri A; Salvia G; Vespasiani G; Santelli G; Cimino S; Allegro R; Collura Z; Fragalà E; Arnone S; Pareo RM
    Prostate; 2014 Nov; 74(15):1471-80. PubMed ID: 25154739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.
    Willetts KE; Clements MS; Champion S; Ehsman S; Eden JA
    BJU Int; 2003 Aug; 92(3):267-70. PubMed ID: 12887481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
    Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
    Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial.
    Lopatkin N; Sivkov A; Walther C; Schläfke S; Medvedev A; Avdeichuk J; Golubev G; Melnik K; Elenberger N; Engelmann U
    World J Urol; 2005 Jun; 23(2):139-46. PubMed ID: 15928959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study.
    Vahlensieck W; Theurer C; Pfitzer E; Patz B; Banik N; Engelmann U
    Urol Int; 2015; 94(3):286-95. PubMed ID: 25196580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
    Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
    Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
    Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
    BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.